Regeneron Pharmaceuticals, Inc.
Regeneron Provides Business Updates at J.P. Morgan Healthcare Conference
Summary
Regeneron Pharmaceuticals, Inc. shared corporate progress and highlights from its broad and diverse investigational pipeline at the 43rd Annual J.P. Morgan Healthcare Conference. The company's marketed products, including Dupixent, EYLEA HD, EYLEA, and Libtayo, reported significant updates. Dupixent saw continued growth and expansion in multiple indications. EYLEA HD and EYLEA remained the U.S. anti-VEGF category leader in 2024. Libtayo exceeded $1 billion in sales for 2024 and demonstrated a significant clinical benefit in high-risk cutaneous squamous cell carcinoma (CSCC). Regeneron also provided updates on its industry-leading pipeline, with numerous promising drug candidates across diverse disease states.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement